This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01283386
First received: January 18, 2011
Last updated: November 1, 2016
Last verified: November 2016
  Purpose
This multi-center, randomized study will compare the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in patients with previously untreated B-cell chronic lymphocytic leukemia and unfavourable somatic status. Patients will be randomized to receive Mabthera (375 mg/m2 intravenously [iv] Day 1 of Cycle 1, 500 mg/m2 iv Day 1 Cycles 2-6) with either fludarabine (20 mg/m2 iv or 32 mg/m2 orally Days 1-3) and cyclophosphamide (150 mg/m2 iv or orally Days 1-3) or with chlorambucil (10 mg/m2 orally Days 1-7) for 6 cycles of 28 days. Anticipated time on study treatment is 24 weeks.

Condition Intervention Phase
Lymphocytic Leukemia, Chronic Drug: chlorambucil Drug: cyclophosphamide Drug: fludarabine Drug: rituximab [MabThera] Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Therapy response rate [ Time Frame: 60 months ]
  • Duration of response [ Time Frame: 60 months ]
  • Overall survival [ Time Frame: 60 months ]
  • Progression-free survival [ Time Frame: 60 months ]
  • Event-free survival [ Time Frame: 60 months ]
  • Safety:Incidence of adverse events [ Time Frame: 60 months ]
  • Laboratory predictors of response [ Time Frame: 60 months ]

Enrollment: 18
Study Start Date: April 2011
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: cyclophosphamide
150 mg/m2 iv or orally on Days 1-3 of each 28-day cycle, 6 cycles
Drug: fludarabine
20 mg/m2 iv or 32 mg/m2 orally Days 1-3 of each 28-day cycle, 6 cycles
Drug: rituximab [MabThera]
375 mg/m2 iv on Day 1 of cycle 1, 500 mg/m2 iv on Day 1 of cycles 2-6 (28-day cycles)
Active Comparator: B Drug: chlorambucil
10 mg/m2 orally on Days 1-7 of each 28-day cycle, 6 cycles
Drug: rituximab [MabThera]
375 mg/m2 iv on Day 1 of cycle 1, 500 mg/m2 iv on Day 1 of cycles 2-6 (28-day cycles)

  Eligibility

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, 60-70 or >70 years of age
  • Cumulative Illness Rating Scale (CIRS) comorbidity score >/=7 if patient is 60-70 years old
  • Previously untreated B-cell chronic lymphocytic leukemia
  • Binet stage B, C or A with progression
  • ECOG performance status 0-2

Exclusion Criteria:

  • Small-cell lymphoma
  • Autoimmune hemolytic anemia
  • Concomitant malignant disease during enrollment, except for basal cell carcinoma of the skin
  • Chemotherapy for concomitant malignant disease within 12 months prior to study enrollment
  • Richter's syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01283386

Locations
Russian Federation
Irkutsk, Russian Federation, 664079
Kemerovo, Russian Federation, 650066
Moscow, Russian Federation, 115478
Moscow, Russian Federation, 125284
Saint-Petersburg, Russian Federation, 198205
St. Petersburg, Russian Federation, 197110
Tula, Russian Federation, 300053
UFA, Russian Federation, 450005
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01283386     History of Changes
Other Study ID Numbers: ML25137
Study First Received: January 18, 2011
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Cyclophosphamide
Fludarabine phosphate
Rituximab
Chlorambucil
Fludarabine
Vidarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on August 22, 2017